Lumos Diagnostics logo

Lumos Diagnostics(ASX) LDX

Market CapA$97.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-91%
5 Year-89%
1 Year-46%
1 Month-2%
A$0.10
-2.00%
-0.00Today
Lumos Diagnostics last closing stock price
MetricPriceDate
Last closeAUD 0.102026-10-12
Lumos Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2%AUD 0.102026-10-05
1 month-2%AUD 0.102026-09-11
3 month+13.95%AUD 0.092026-07-14
Year to date-65.61%AUD 0.292025-12-31
1 year-45.56%AUD 0.182025-10-10
3 year-2%AUD 0.102023-10-13
5 year-89.23%AUD 0.912021-10-13
Since inception-91.17%AUD 1.132021-07-05

Lumos Diagnostics Financials at a Glance

Market Cap

A$97.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$25.60M

Net Income (TTM)

-$12.22M

EPS (TTM)

-A$0.01

P/E Ratio

-10.20

Dividend

A$0.00

Beta (Volatility)

0.06 (Low)

Price

A$0.10

Volume

3,499,671

Open

A$0.10

Previous Close

A$0.10

Daily Range

A$0.10 - A$0.10

52-Week Range

A$0.08 - A$0.33

Estimated Earnings Date

Mar 4, 2027

LDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lumos Diagnostics

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for infectious diseases. The company focuses on innovative solutions that enhance patient care and streamline diagnostic processes in the United States.

Products and Services
  • FebriDx: A test for differentiating viral and bacterial respiratory infections
  • ViraDx: A three-in-one test for influenza A, influenza B, and COVID-19
  • Assay development and manufacturing services for point-of-care tests
Growth Outlook
  • Recent quarterly revenue reached USD 6.97 million, indicating strong market demand
  • Expansion into new markets is anticipated to drive future revenue growth
  • Investment in R&D aims to enhance product offerings and market competitiveness
Financial Highlights
  • Trailing twelve months (TTM) revenue of USD 25.5 million reflects a growing customer base
  • Cash and cash equivalents stood at USD 15.42 million as of June 30, 2026
  • Operating cash flow improved significantly, reaching USD 192,096 in the latest quarter
Lumos Diagnostics Holdings Limited is positioned in the healthcare sector, specifically within medical specialties. The company has shown resilience in its financial performance, with a notable increase in quarterly revenue and cash reserves. The focus on innovative diagnostic solutions, coupled with a strategic growth plan, suggests a promising trajectory for future development. Investors may find the company's commitment to enhancing diagnostic capabilities and expanding its market presence appealing as it navigates the evolving healthcare landscape.
AI Generated • Sep 20, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Douglas Ward

Website

www.lumosdiagnostics.com

Headquarters

Melbourne, VIC 3000, AU

LDX Financials

Key Financial Metrics (TTM)

Gross Margin

-58.54%

Operating Margin

-107.10%

Net Income Margin

-38.18%

Return on Equity

-35.89%

Return on Capital

-50.16%

Return on Assets

-12.37%

Earnings Yield

-9.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$97.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

971.67M

Volume

3.50M

Avg. Volume

1.64M

Financials (TTM)

Gross Profit

-$50.02K

Operating Income

-$19.68M

EBITDA

-$17.20M

Operating Cash Flow

-$8.36M

Capital Expenditure

-$2.55M

Free Cash Flow

-$10.91M

Cash & ST Invst.

$15.42M

Total Debt

$5.94M

Lumos Diagnostics Performance Analysis

Lumos Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 15,660,665-2.3%
20242024-06-30USD 16,984,1698.5%
20252025-06-30USD 19,146,70612.7%
20262026-06-30USD 19,468,0541.7%
Lumos Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-30-24.6%
Q42025-06-30-3.4%
Q22025-12-312.3%
Q42026-06-3011.9%
Lumos Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -0.05-86.3%
20242024-06-30USD -0.03-50.1%
20252025-06-30USD -0.02-38.7%
20262026-06-30USD -0.01-44.8%
Lumos Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-30N/A
Q42025-06-30-26.1%
Q22025-12-31-10.3%
Q42026-06-3098.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$6.97M

-16.7%

Gross Profit

-$4.65M

-190.7%

Gross Margin

-66.76%

N/A

Market Cap

A$97.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$3.35M

N/A

Employees

29

N/A

Net Income

-$70.97K

+96.7%

EBITDA

-$6.26M

-868.8%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$15.42M

+138.0%

Total Debt

$5.94M

-26.3%

Accounts Receivable

$2.22M

+230.2%

Inventory

$1.64M

+109.2%

Long Term Debt

$4.88M

-31.4%

Short Term Debt

$1.06M

+11.3%

Return on Assets

-12.37%

N/A

Return on Invested Capital

-51.00%

N/A

Free Cash Flow

-$2.11M

-136.8%

Operating Cash Flow

$192.10K

-96.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CTE.AXCryosite Limited
A$1.21+0.00%
IIQ.AXINOVIQ Ltd
A$0.16+0.00%
GSS.AXGenetic Signatures Limited
A$0.08-5.95%
AT1.AXAtomo Diagnostics Limited
A$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$34.39+1.78%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$139.76-1.94%
WFFWf
$12.29+499.51%
IRENIren
$35.19-1.46%

Questions About LDX

What is the current price of Lumos Diagnostics?

Lumos Diagnostics is trading at A$0.10 per share.

What is the 52-week range for Lumos Diagnostics?

Over the past 52 weeks, Lumos Diagnostics has traded between A$0.08 and A$0.33.

How much debt does Lumos Diagnostics have?

As of the most recent reporting period, Lumos Diagnostics reported total debt of $8.57M.

How much cash does Lumos Diagnostics have on hand?

Lumos Diagnostics reported $22.27M in cash and cash equivalents in its most recent financial results.

What is Lumos Diagnostics’s dividend yield?

Lumos Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services